Going Early For Maximum Long Term Value From Medtech Deals

For Medtech Deal-Makers The Best Opportunities Must Be Developed Well In Advance Of M&A

Strategics pursuing high growth M&A plays are often ready to pay a premium price for a target. But with medtech valuations at historic highs, they cannot afford to do that every time. One solution is to take a strategic stake and build early, according to an AdvaMed panel hosted by EY’s John Babitt.

business card

“I would never have thought 2021 would turn out as it did,” said John Babitt, a Minneapolis-based partner with EY. He was referring to the uncharted heights achieved last year in medtech M&A deal-making and venture capital funding.

For 2021 as a whole, $111bn was paid out on 64 medtech M&A deals. Both of these were record numbers,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Intelligence

More from In Vivo